IRIDEX CORP

IRIDEX CORP (IRIX) received a notification from Nasdaq indicating its common stock has fallen below the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company has 180 days, until February 23, 2027, to regain compliance. During this period, the stock will continue to trade on Nasdaq without immediate impact. IRIDEX is exploring options to meet the requirement, with potential for an additional 180-day extension if specific conditions are met, including a reverse stock split. Failure to comply could lead to delisting.

IRIDEX Corporation announced its plan to release financial results for the second quarter of 2026 after the close of trading on August 18, 2026. The company will host a corresponding conference call and webcast on the same day at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results and provide a business update. Investors can access the call via dial-in numbers or through the company's website.

Iridex Corporation announced the expansion of its EyeProGPO product offering to include its EndoProbe Handpieces. This agreement provides over 4,300 EyeProGPO members with access to preferred pricing on these devices, which are used for treating retinal disorders. The expansion strengthens Iridex's collaboration with EyeProGPO and enhances access to its retina laser portfolio for ophthalmology practices, ambulatory surgery centers, and hospitals across the U.S.

IRIDEX Corporation's Annual Meeting of Stockholders reconvened on July 10, 2026, where all director nominees were elected, BPM LLP was ratified as auditor, and executive compensation was approved. However, the company's board alleges a 'stealth proxy campaign' by its largest stockholder, Novel Inspiration International Co., Ltd., and director William Moore. The board claims this campaign involved violations of fiduciary duties and federal securities laws, causing embarrassment and potential liability, particularly regarding efforts to influence director elections and a proposal to reprice Series B preferred stock conversion.

IRIDEX Corporation announced that its 2026 annual meeting of stockholders, initially convened on June 12, 2026, was adjourned without conducting any business. The meeting is scheduled to reconvene on Friday, July 10, 2026, at 8:00 a.m. Pacific Time, at the company's principal executive offices. All proposals and the record date of April 17, 2026, remain unchanged, and previously submitted proxies will be honored.

IRIDEX reported a significantly reduced net loss of $0.52 million for the first quarter ended April 4, 2026, compared to a net loss of $1.69 million in the prior year. Diluted EPS improved to $(0.03) from $(0.10). However, total revenues saw a slight decrease to $11.80 million from $11.90 million year-over-year, and gross profit also declined. The company continued to use cash in operating activities.

Iridex Corporation reported its first-quarter 2026 financial results, with total revenue of $11.8 million, a slight decrease from the prior year, and a net loss of $0.5 million, an improvement from the $1.7 million loss in Q1 2025. The company saw 14% year-over-year growth in Cyclo G6 product family revenue, reaching $3.6 million, while retina product revenue declined due to international supply constraints. Iridex affirmed its full-year 2026 revenue guidance of $51 million to $53 million and expects to generate positive operating cash flow for the fiscal year.

Iridex Corporation reported Q1 2026 financial results with total revenue of $11.8 million, a 1% decrease year-over-year. The company saw strong growth in its Cyclo G6 product family revenue, up 14% to $3.6 million, while retina product revenue declined due to international supply constraints. Operating expenses were reduced by 4%, leading to a significantly improved net loss of $0.5 million compared to $1.7 million in the prior year. Iridex reaffirmed its full-year 2026 revenue guidance of $51 million to $53 million and expects to generate positive operating cash flow for the fiscal year.

Iridex Corporation announced its plans to release financial results for the first quarter of 2026 after the close of trading on May 19, 2026. Following the release, the company's management team will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results and provide a business update. Investors can access the call via phone or a live and recorded webcast on the company's investor relations website.

IRIDEX Corporation announced its Annual Meeting of Stockholders will be held on June 12, 2026, at 8:00 a.m. Pacific time. Stockholders will vote on the election of five directors, the ratification of BPM LLP as the independent registered public accounting firm for fiscal year 2026, and an advisory vote on named executive officer compensation. The record date for voting is April 17, 2026, with proxy materials available online and mailed around May 1, 2026.